

Hancock County Chamber of Commerce,
123 E. Main Cross Street, Findlay, Ohio
45840.

Dated: March 5, 2003.

Dennis Puccinelli,

Executive Secretary.

[FR Doc. 03-6086 Filed 3-12-03; 8:45 am]

BILLING CODE 3510-DS-P

DEPARTMENT OF COMMERCE

International Trade Administration

[A-570-853]

Notice of Amended Final Results of Antidumping Duty Administrative Review: Bulk Aspirin from the People's Republic of China

AGENCY: Import Administration,
International Trade Administration,
Department of Commerce.

ACTION: Notice of amended final results
of antidumping duty administrative
review.

EFFECTIVE DATE: March 13, 2003.

FOR FURTHER INFORMATION CONTACT: Julie
Santoboni or Cole Kyle, Office 1, AD/
CVD Enforcement, Import
Administration, International Trade
Administration, U.S. Department of
Commerce, 14th Street and Constitution
Avenue, NW., Washington DC 20230;
telephone (202) 482-4194 or (202) 482-
1503, respectively.

Scope of Review

The product covered by this review is
bulk acetylsalicylic acid, commonly
referred to as bulk aspirin, whether or
not in pharmaceutical or compound
form, not put up in dosage form (tablet,
capsule, powders or similar form for
direct human consumption). Bulk
aspirin may be imported in two forms,
as pure ortho-acetylsalicylic acid or as
mixed ortho-acetylsalicylic acid. Pure
ortho-acetylsalicylic acid can be either
in crystal form or granulated into a fine
powder (pharmaceutical form). This
product has the chemical formula
 $C_9H_8O_4$. It is defined by the official
monograph of the United States
Pharmacopoeia ("USP") 23. It is
classified under the Harmonized Tariff
Schedule of the United States
("HTSUS") subheading 2918.22.1000.

Mixed ortho-acetylsalicylic acid
consists of ortho-acetylsalicylic acid
combined with other inactive
substances such as starch, lactose,
cellulose, or coloring materials and/or
other active substances. The presence of
other active substances must be in
concentrations less than that specified
for particular nonprescription drug
combinations of bulk aspirin and active
substances as published in the
Handbook of Nonprescription Drugs,
eighth edition, American
Pharmaceutical Association. This
product is classified under HTSUS
subheading 3003.90.0000. Although the
HTSUS subheadings are provided for
convenience and customs purposes, the
written description of the merchandise
under investigation is dispositive.

Amended Final Results

On February 4, 2003, the Department
of Commerce ("the Department")
determined that bulk aspirin from the
People's Republic of China ("PRC") is
not being sold in the United States at
less than normal value, as provided in
section 751(a) of the Tariff Act of 1930,
as amended ("the Act"). See *Bulk
Aspirin from the People's Republic of
China; Final Results of Antidumping
Duty Administrative Review* ("Final
Results"), 68 FR 6710 (February 10,
2003). On February 7 and 10, 2003,
Shandong Xinhua Pharmaceutical Co.,
Ltd. ("Shandong") and Rhodia, Inc.
("petitioner"), respectively, filed timely
ministerial error allegations pursuant to
19 CFR 351.224(c)(2). On February 12,
2003 the petitioner filed a reply to
Shandong's allegation and on February
18, 2003, Shandong filed a response to
the petitioner's February 12, 2003
submission. The other respondent in
this review, Jilin Henghe
Pharmaceutical Company Ltd. ("Jilin"),
did not file a ministerial error
allegation.

The petitioner contends that the
Department incorrectly rounded one of
the surrogate values for caustic soda,
incorrectly deducted taxes from the
domestic price of acetic acid sold on the
Mumbai Dyes Market and assigned the
incorrect surrogate labor value for
packing labor in Jilin's normal value
calculations. The petitioner also alleges
that the Department overstated the
excise and sales taxes for all domestic
values because the deduction of taxes

from the *International Chemical Weekly*
("ICW") domestic prices was based on
the gross price, when instead it should
have been based on the before-tax price.
Furthermore the petitioner asserts that
the Department did not calculate a
portion of the normal value build up
associated with one of the inputs.
Neither Shandong nor Jilin responded to
petitioner's comments.

Shandong contends that the
Department incorrectly used a single
surrogate value for virgin acetic acid to
value all the acetic acid inputs in its
calculation of the cost of acetic
anhydride production, when instead it
should have valued the virgin and
recovered acetic acid separately. The
petitioner contends that the Department
correctly applied the surrogate value of
virgin acetic acid to the full quantity of
acetic acid used in the production
process and that Shandong ignores the
distinction between "recovered" acetic
acid and "recycled" or "reused" acetic
acid. In its response to the petitioner's
comments, Shandong argues that
recovered, recycled and reused acetic
acid are identical and should have the
same value.

In accordance with section 735(e) of
the Act, we have determined that
certain ministerial errors were made in
our final results margin calculations.
Specifically we find that the incorrect
calculation of certain taxes from the
ICW domestic prices and the incorrect
surrogate value of Jilin's packing labor
constitute clerical errors. For a detailed
discussion of all of the ministerial error
allegations and the Department's
analysis, see Memorandum to Susan
Kuhbach, "Antidumping Duty
Administrative Review of Bulk Aspirin
from the People's Republic of China;
Allegations of Ministerial Errors" dated
March 5, 2003, which is on file in the
Central Records Unit, room B-099 of the
main Department building.

In accordance with 19 CFR
351.224(e), we are amending the final
results of the antidumping duty
administrative review of bulk aspirin
from the PRC to correct these ministerial
errors. However, the amended weighted-
average margins are identical to the
weighted-average margins in the final
results (see *Final Results*). The
weighted-average dumping margins for
Jilin and Shandong are listed below:

Producer/manufacturer/exporter	Original weighted-average margin percentage	Amended results weighted-aver- age margin percentage
Jilin Henghe Pharmaceutical Company Ltd.	0.04 (<i>de minimis</i>)	0.04 (<i>de minimis</i>)
Shandong Xinhua Pharmaceutical Co., Ltd.	0.00	0.00